COVID-19 Immunity From mRNA Booster Does Not Last Very Long.
Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to 115 days...
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we follow, shows a spike in either...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
We're adding Citius Pharma to the Watch...
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class...
GeoVax (GOVX) Launches Vaccine Manufacturing System.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines
ATLANTA, GA,...
Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief...
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC)...
Major Mpox Outbreak in the Democratic Republic of Congo.
As Reported in NPR's Gates and Soda
Major Mpox Outbreak in the Democratic Republic of Congo is a Worry to Disease docs.
UPDATED APRIL 2, 2024
"It's...
Mpox Infections Rise to Almost Double Last Year’s Numbers.
The number of mpox cases in 2024 is already nearly double the number of cases that were detected in all of 2023.
The most recent...
Adding Asia Broadband (AABB) to Speculative Watch List.
Asia Broadband, Gold Play With Digital Currency (NFT) Twist
The last speculative stock trading under $0.05, that we added to the Watch List was Pharamather...
GeoVax to Present at World Vaccine Congress, Thursday April 4th.
Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company’s next-generation non-MRNA Covid-19 vaccine candidate on Thursday, April 4, 2024, 12:00...